STOCK TITAN

Corcept Therapeutics Inc. - $CORT STOCK NEWS

Welcome to our dedicated page for Corcept Therapeutics news (Ticker: $CORT), a resource for investors and traders seeking the latest updates and insights on Corcept Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Corcept Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Corcept Therapeutics's position in the market.

-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.19%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.62%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.76%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.02%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.48%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.26%
Tags
Corcept Therapeutics Inc.

Nasdaq:CORT

CORT Rankings

CORT Stock Data

2.55B
84.92M
11.41%
83.63%
20.61%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
MENLO PARK

About CORT

leading the field in the discovery of drugs that modulate the effects of cortisol the adverse effects of excess cortisol have been corcept’s focus since the company’s inception. abnormal levels and release of cortisol play a role in a variety of metabolic, oncological, and psychiatric diseases, and we are currently studying a new generation of compounds that may mitigate the effects of excess cortisol. in addition to our work with mifepristone, we have developed over 300 proprietary molecules, advancing the most promising of these to the clinic to see if they can mitigate the effects of excess cortisol and the serious, sometimes life-threatening conditions that may result. all of these compounds competitively block the glucocorticoid receptor (gr), but not the progesterone receptor. scientific literature suggests that competitive gr antagonism may have a role in treating many conditions, including post-traumatic stress disorder, mild cognitive impairment, alzheimer’s disease, alcoholis